Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.
Sponsor: TG Therapeutics, Inc.
A PHASE1 clinical study on Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by TG Therapeutics, Inc. and has accumulated 11 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TG Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .